Revenue segments as reported by the company.

Product sales

Royalty, contract and other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Acquired in-process research and development expenses

Selling, general and administrative

In-process research and development impairment

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Gilead Sciences reports robust earnings, eyes pipeline opportunities for growth

Gilead Sciences delivered strong financial performance in Q4 2022, driven by growth in key product sales. Despite facing challenges in the HIV market for Q1 2023, the company remains focused on leveraging opportunities in its pipeline and strategic investments.

Gilead reports strong Q1 sales, focuses on pipeline growth

Gilead Sciences delivered strong sales driven by key products in Q1 2023.
While facing challenges like lower Veklury sales, Gilead maintains revenue guidance.
The company's strengths lie in its pipeline, successful products, and manufacturing capabilities.
Opportunities in new indications and therapies position Gilead for future growth.

Gilead Sciences reports robust Q2 performance and eyes future growth

Gilead Sciences had a strong quarter with growth in sales and positive pipeline updates.
Trodelvy's performance in different markets and potential Medicare coverage are key highlights.
Challenges include unsuccessful trials and addressing revenue aspirations.
Opportunities lie in expanding BD activities and exploring cell therapy beyond oncology.

Gilead Sciences reports robust Q3 performance amidst market challenges

Gilead Sciences demonstrated strong performance in Q3 2023, driven by growth in base business, oncology, and HIV segments.
While facing challenges such as declining Veklury sales and barriers to CART therapy uptake, Gilead is actively addressing opportunities for growth and market expansion.
The company's strengths lie in robust product sales, particularly in Biktarvy and Trodelvy, with a focus on innovation and strategic positioning in key therapeutic areas.
Overall, Gilead's performance reflects resilience and strategic planning amidst evolving market dynamics and competitive landscapes.

Gilead Sciences reports strong 2023 performance, eyes transformative therapies

Gilead Sciences showcased solid performance in 2023 with notable growth in key product sales areas, despite facing challenges in certain clinical trials. The company's strengths lie in its diverse portfolio, pipeline innovation, and commitment to delivering transformative therapies. With a focus on addressing HIV, oncology, and inflammation, Gilead is well-positioned for future growth and success.

Gilead Sciences reports robust Q1 performance and eyes future growth

Gilead Sciences delivered strong Q1 results driven by oncology and HIV product sales.
Challenges include IP R&D charge from Sema Bay acquisition and competitive market dynamics.
Opportunities lie in expanding cell therapy leadership, advancing HIV pipeline, and upcoming pipeline updates.
Overall, Gilead remains focused on growth through innovation and strategic portfolio advancements.

Gilead Sciences reports robust Q3 performance and eyes market expansion

Gilead Sciences' Q3 performance reflects strong revenue growth and market leadership in key segments, supported by successful product launches and strategic initiatives.
The company's focus on innovation, patient-centric approaches, and market expansion bodes well for future growth and competitive positioning.
While challenges in maintaining growth and managing expenses exist, Gilead's proactive stance on addressing market needs and leveraging opportunities positions it for continued success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The new coronavirus made Dr. Jag Singh a patient at his own hospital.

Coronavirus patients eagerly join Gilead Sciences drug study

Gilead Sciences, Inc.'s (NASDAQ: GILD) remdesivir is one of the frontrunners among investigational drugs to treat COVID-19.

Gilead Analyst Sees Catalyst Ahead In Data Readout For Potential Coronavirus Treatment

Gilead And The Economics Of Remdesivir

The biotech has manufactured enough doses to treat over 140,000 patients infected with the new coronavirus and is looking to further ramp up production.

Gilead Has Treated More Than 1,700 COVID-19 Patients With Remdesivir

Gilead Sciences, Inc. (NASDAQ: GILD) is donating 1.5 million doses of remdesivir, its investigational drug for COVID-19, for compassionate use, expanded access and clinical trials, Chairman and CEO Daniel O'Day said Saturday.

Gilead To Donate 1.5M Doses Of Experimental Coronavirus Treatment: 'The Right Thing To Do'

Quest Diagnostics

Johnson & Johnson

Teladoc

Zoom Video

These companies are helping us fight COVID-19. They can also help you protect and grow your wealth during the pandemic.

The 5 Best Coronavirus Stocks To Buy Right Now

Should You Buy Gilead Sciences Stock Right Now?

Good news from trials of Remdesivir could send the stock soaring.

Why Gilead Sciences Is the Hottest Stock to Buy Today

Accenture Plc

Check Point Software Technologies

Mastercard

5 Stocks That Outperformed Last Recession And Will Likely Outperform This One

Gilead Sciences is working on a coronavirus treatment, while GILD stock works on a breakout. Let's examine it more closely.

Gilead Sciences’ Coronavirus Treatment Has Big-Time Potential

Netflix

PayPal

By Kayla Matthews, Journalist & Writer COVID-19 has thrown the world into uncertainty. The stock market responded with tremendous plunges that may have made you scared to ever buy stocks again.

The Safest Investments to Make During The COVID-19 Chaos

AbbVie

BioCryst Pharmaceuticals

Regeneron Pharmaceuticals

Roche Holding AG

Biotech Companies In The Race To Find COVID-19 Treatment

Accessing the experimental antiviral treatment outside of clinical trials just got easier in the European Union.

EMA Recommends Remdesivir for Treatment of COVID-19 Under Compassionate-Use Rules

The promise of Gilead’s coronavirus treatment lifted the shares.

Why Gilead Sciences Shares Rose 7.79% in March

Biogen

With everything going on in the markets right now, which of these two biotech stocks is the better investment?

Better Buy:  Gilead Sciences vs.  Biogen

Clorox

Citrix Systems

Digital Realty Trust

MSCI

NortonLifeLock

NVIDIA

SBA Communications

Just 6% of stocks in the S&P 500 made gains in the first quarter.

These 10 Stocks Jumped During The Market’s Worst Quarter Since 1987

Gilead Science’s clinical trial for remdesivir continues. With or without it, GILD stock remains a smart play.

GILD Stock Remains a Smart Play Now and in the Future

Bristol-Myers

With the coronavirus pandemic pushing stock prices to historic lows, there are plenty of promising companies to invest in today.

Top 3 Healthcare Stocks to Buy Right Now

Air Products and Chemicals

Alphabet

Intuit

Lam Research

We finally made it to the second quarter after a March that seemed to last forever, and we pretty much started off the same way it ended, with more selling.

5 Blue Chip Stocks to Buy Now With Huge Piles of Cash and Very Low Debt

Abbott Labs

Their coronavirus programs are only part of the attraction for these two healthcare giants.

Better Coronavirus Stock: Abbott Labs vs. Gilead Sciences

Moderna

Here's why these two pharma giants can carry you through the COVID-19 pandemic and beyond.

My Top Pharma Stocks to Buy in the Market Crash

Here Are 10 Stocks Beating The Coronavirus Bear Market

CRISPR Therapeutics

Telesis Bio Inc

Vir Biotechnology

These biotech stocks are all working on treatments that have the potential to beat the coronavirus. Don't just wait for a cure.

7 Biotech Stocks to Buy That Could Beat the Coronavirus

In the latest trading session, Gilead Sciences (GILD) closed at $74.76, marking a -1.54% move from the previous day.

Gilead Sciences (GILD) Stock Moves -1.54%: What You Should Know

Good Reason To Be Hopeful For Gilead's Remdesivir

News for Gilead Sciences Stock (GILD)